Return to work following diagnosis of low-grade glioma Only half of patients with a low grade glioma return to work in the first year. 5% of Glioblastoma patients are working at the 1 year point. This underscores the devastation that a diagnosis of a brain tumor - even low grade - can bring to a family. The ability to work at 1 year (at a level they worked before the tumor) should be an important endpoint for clinical trials.
Medexus gets Health Canada nod to market tumor imaging material Gleolan for neurosurgery Gleolan is finally approved in Canada. It has been standard of care in Europe for many years before it was approved in the USA 3 years ago. According to the article cited , it doubles the chance of a complete resection, and doubles the 6 month progression free survival rate. This is a dye used at the time of surgery to make it easier for the surgeon to identify where the tumor is.